Chronic Graft-Versus-Host Disease Following Intestine, Liver, Pancreas, and Stomach Transplantation (ACG 2026) - Aug 29, 2026 - Abstract #P2090; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "Therapy escalates from everolimus and octreotide to capecitabine and temozolomide, with subsequent disease progression...Dermatology and hematology are consulted, topical steroids are started for the rash and tbo-filgrastim for worsening neutropenia...After refusing cytogam, he returns with rising CMV levels, is treated with IV ganciclovir, and discharged with oral valganciclovir...Persistent donor predominance on STR analysis with cutaneous and bone marrow involvement is shown. Treatment includes corticosteroids, etanercept, photopheresis, ruxolitinib, and supportive care."
Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Gastrointestinal Neuroendocrine Tumor • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Leukopenia • Neuroendocrine Tumor • Neutropenia • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • Solid Tumor • Transplantation
|
|
Yasmeen Jazaerly BS 1; Yakir Muszkat MD 2; Nemie Beltran RN 3; Syed-Mohammed Jafri MD 3
|